These four top dividend stocks offer dependable passive income streams and solid total return, and they are too cheap to ...

Here are three dividend stocks that retirees can buy with confidence as they offer recurring, dependable payouts and a degree ...

The pharma expects a modest financial headwind this year from changes to Medicare prescription drug benefits under the ...

Bristol-Myers Squibb (NYSE:BMY), a global biopharmaceutical company with a market capitalization of nearly $120 billion, finds itself at a critical juncture as it navigates a complex landscape of ...

AbbVie (NYSE:ABBV) has managed to keep its market share for its bestselling arthritis therapy, Humira, above 70%, generic ...

Viatris has faced volatility since its 2020 formation but is now in Phase 2 of its transformation. Learn why VTRS stock could ...

Johnson & Johnson has come out fighting after Pfizer announced yesterday that it is ready to launch a biosimilar competitor to its blockbuster Remicade. J&J said it had a “biosimilar ...

Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation ...

Amgen's dividend profile shines, but growth slows. See why AMGN stock faces regulatory risks and offers limited incentives ...

India's pharmaceutical industry is set for growth, driven by strong market players, global reputation, and evolving trends.

Pfizer is suing Johnson & Johnson, alleging that it induced US health insurers to help it block biosimilar competition to its blockbuster Remicade. Pfizer's Inflectra was the first monoclonal ...

Pfizer's dividend is safer than it might seem ... Now, though, Humira's sales are falling as it faces biosimilar competition. The good news is that AbbVie has prepared well for this scenario.